Samsara Bio Capital, LLC Intercept Pharmaceuticals, Inc. Transaction History

Samsara Bio Capital, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$12.53 - $21.71 $8.03 Million - $13.9 Million	640,688 New	640,688 $8.6 Million
Q1 2021 May 18, 2021	BUY	$19.33 - $37.75 $4.58 Million - $8.95 Million	237,000 Added 58.71%	640,688 $14.8 Million
Q3 2019 Nov 14, 2019	BUY	$58.69 - $80.46 $4.28 Million - $5.87 Million	72,991 Added 22.07%	403,688 $26.8 Million
Q2 2019 Aug 14, 2019	BUY	$77.77 - $120.68 $9.31 Million - $14.5 Million	119,760 Added 56.78%	330,697 $26.3 Million
Q1 2019 May 15, 2019	SELL	$91.83 - $120.68 $2.15 Million - $2.83 Million	-23,438 Reduced 10.0%	210,937 $23.6 Million
Q4 2018 Feb 14, 2019	BUY	$85.79 - $126.46 $20.1 Million - $29.6 Million	234,375 New	234,375 $23.6 Million

1.04M

30K

5.9K

Ticker ICPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 41,127,400
Description
Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination wit...

Get notified when there are updates to the investment portfolio of Samsara Bio Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Samsara Bio Capital, LLC with notifications on news.